Ensartinib - Betta Pharmaceuticals/Xcovery

Drug Profile

Ensartinib - Betta Pharmaceuticals/Xcovery

Alternative Names: X-396

Latest Information Update: 08 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xcovery
  • Developer Betta Pharmaceuticals Co Ltd; Cancer Research Institute; Ludwig Institute for Cancer Research; MedImmune; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Xcovery Holdings
  • Class Antineoplastics; Piperazines; Pyridazines; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; EphA2 receptor antagonists; Proto oncogene protein c met inhibitors; ROS1-protein-inhibitors; TrkA receptor antagonists; TrkC receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II CNS cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 10 Jan 2018 Phase-II clinical trials in Malignant melanoma (Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT03420508)
  • 04 Jan 2018 Chemical structure information added
  • 28 Sep 2017 Phase-II clinical trials in Non-small cell lung cancer (Metastatic disease, Second-line therapy or greater, Late-stage disease) in China (PO) (NCT03215693)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top